FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549	
------------------------	--

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number: 3235-0287										
Estimated average burden										
hours per re	esponse:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar ABERT (Last) 12780 El	NE NB 3. Da 01/3	Issuer Name and Ticker or Trading Symbol     NEUROCRINE BIOSCIENCES INC [     NBIX ]  3. Date of Earliest Transaction (Month/Day/Year)     01/31/2023									(C	Relationship of Repo heck all applicable) Director X Officer (give tit below) Chief Fir			ncial	10% O Other ( below)	wner specify				
(Street) SAN DII			4. lf	4. If Amendment, Date of Original Filed (Month/Day/Year)									Indivi ne) X								
(City)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yea				ar) if	2A. Deemed Execution Date,			3. Transaction					(A) or		5. Ame Secur Benef Owner Follow	Securities Beneficially Owned		ownership m: Direct or rect (I) tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					_		C		v		iount	(A) or (D)	L	rice	<b>7</b> (2)	Transaction(s) (Instr. 3 and 4)					
Common Stock 01/31/2023									S <sup>(1)</sup>			1,283	D	L	109.982			1,357		D	
		Tal	ble	II - Derivati (e.g., pu													wne	d			
1. Title of Derivative Security (Instr. 3)	Title of 2. 3. Transaction Sal. Deemed Execution Date, or Exercise (Month/Day/Year) if any				Transaction Code (Instr. 8) Se Ac (A) Dis			osed ) : 3, 4	Exi (Mo	piratio onth/D	on Date Day/Year)			ouri derl riva curi nd	Amount or Number	8. Price Derivat Securit (Instr. 5		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Da:	te ercisal	ole	Expiration Date		Title Share							

## **Explanation of Responses:**

1. Sale of 1,283 shares of common stock issued upon vesting of 2,436 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,153) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

## Remarks:

/s/ Darin Lippoldt, Attorney-

02/02/2023

in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>2.</sup> Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$109.07 to \$110.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.